What: Possibly the biggest breakthrough in modern cancer medicine which consistently helps patients get better treatment outcomes.
How: Timing cancer treatments with a patient’s immune cycle: Simple, safe, inexpensive
Outcomes: Even stage 4 patients have achieved remission in the trials.
With this method, clinical evidence shows that just one dose of ‘limited’ therapy (chemo, radiation, immunotherapy) is needed for ‘maximum therapeutic effect.’ (A complete response)
Method: To achieve this outcome the therapy must be delivered at the correct time (a narrow therapeutic window) in the patient’s repeating 7-day immune cycle.
In other words: If your doctor times your normal cancer treatments in synchrony with your own 7-day immune cycle you may get an excellent healing response – remission etc.
To this end we have created an Immune Registry Pilot Program.
I hope you have allowed time to reflect on how this breakthrough can impact you. Many patients are ‘so busy rushing around’ they miss the gold under their noses’
Time for Action:
- Join the Registry Pilot Program today – you may drastically increase your recovery chances, yes remission is a possibility.
- Joining our patient power movement may influence governments to act. We believe cancer patients have a right to access the latest potentially life-saving research.
- Patient Power Participation will surely encourage governments to adopt viable new cancer treatments in a more timely fashion – you can help to make a difference.
Want more research?
The following interview provides more information:
Select the green button below to listen or download audio – The Answer to Cancer – How Your Immune Body-Clock can assist Complete Remission – Navigating the Cancer Maze – weekly on VoiceAmerica
Mayo Clinic: Svetomir Markovic, M.D., Ph.D., explains how his research at the Mayo Clinic, which is focused on understanding opportunities to integrate different systemic treatment modalities into more-effective therapies for advanced melanoma – including timing of treatment
(Note: credits to Ashdown & Coventry at end of video)
All of Dr. Markovic’s research activities are centered on the principle of developing more effective and less toxic therapies for advanced cancers. A professor of oncology and haematology his focus is translational immunotherapeutics of cancer especially malignant melanoma and non-Hodgkin’s lymphoma. His work includes development and clinical testing of cancer vaccines, immune-boosting agents, novel agents that reconstitute immunity in patients with cancer, and combination therapy directed at enhancing anti-tumor immune responses.
- Please add your details in an email to Grace – to the form below the clock.
- We will be in touch, sending you a consent form, further information and instructions.
- Please DO NOT register on behalf of a patient.
- Privacy Policy Guarantee: We do not share or disclose your details to any third parties with the exception of Martin Ashdown, a Melbourne based scientist, Research Fellow at the Faculty of Medicine University of Melbourne.
More Information:
Martin & Brendon Coventry are cancer researchers and "immunological explorers" who not only unearthed a buried "treasure"; but they have also created a map for other innovative cancer "explorers" to follow. The "treasure" is a cancer drug used for more than 20 years that is now providing oncologists with new information about how to best help patients achieve complete remission. The drug called interleukin-2, is providing cancer researchers with something akin to how the "Rosetta Stone" was used to unlock historical script; the outcome; mapping the immune cycle! Martin is keen to have his work further tested by others and. As he says, "Please prove me wrong." These are the words of an honest and balanced scientific researcher.
Measuring the Immune Cycle:
The work is based on research performed by Martin Ashdown, a Melbourne based scientist, Research Fellow at the Faculty of Medicine University of Melbourne.
Martin has made the observation that the immune response in the late stage cancer patient is oscillating repeatedly over an approximate seven day period or cycle.
This observation may have profound implications for the timed delivery of various therapies, which via immune modulation may increase complete response rates, reduce toxicity and substantially reduce the cost of treatment.
Martin has co-designed trials at international institutions and presented at international conferences advocating monitoring patients prior to treatment and accurately timing therapy as pulses.
This technique, known as “Immune Synchronization” is believed to already happen accidentally is those patients who successfully respond to therapy with a complete response. Martin and colleagues suggest that the drugs and resources to successfully treat cancer are already here, but need to be used more accurately.
PLEASE NOTE:
This is not a registered trial but a gathering of valuable data that can be analysed and recorded with your consent.
Your participation will make a significant contribution to how cancer therapies are delivered in the future.
DISCLAIMER: Please read the following - Grace Gawler Institute Medical information disclaimer